(HealthDay)—Many patients with type 2 diabetes (T2D) who have a hemoglobin A1c (HbA1c) level expected to trigger treatment intensification often have treatment inappropriately delayed, according to a research letter published in the July issue of Diabetes Care. Kevin M. Pantalone, D.O., from the Cleveland Clinic, and colleagues identified a cohort of 7,389 patients with T2D […]